Compared with A20 mice, the statistically analyzed data demonstrated that systemic CD19-expressing cells, and especially GFP+ CD19+ lymphoma cells, were significantly cleared after anti-CD19 CAR T-cell treatment (Figure 2D). Here, CD19 is linked to lymphoma.